BALI association

Phase 3Small molecule

EEMS

BALI association is one of 11 small molecule programs targeting Aphthous Ulcer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aphthous UlcerActive, not recruiting

Aphthous UlcerPhase 3

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Aphthous Ulcer

#DrugCompanyPhaseTrials

Colcrys

Alnylam Pharmaceuticals

Approved

—2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—3

Kenalog

BBausch Health Americas, Inc.

Advil

Benadryl

Thalomid

1 7

Verazinc

FFakultas Kedokteran Universitas Indonesia

BALI association

1 9

Peridex

Kenalog

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Aphthous Ulcer1 trial

Efficacy and Safety of BALI Association in the Treatment of Aphthous Ulcerations

Unknown status·EEMS·Phase 3·NCT05542173·232 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BALI association. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BALI association compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BALI association. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEMS

BALI association

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Aphthous Ulcer1 trial

References

Drug Info

Quick Facts

Related News